Carrie Krehlik - Sep 1, 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Chief Human Resources Officer
Signature
/s/ Miguel Carrillo, as Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Sep 1, 2021
Transactions value $
$0
Form type
4
Date filed
9/2/2021, 08:00 PM
Previous filing
Aug 3, 2021
Next filing
Mar 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Award $0 +32.2K $0.00 32.2K Sep 1, 2021 Common Stock 32.2K Direct F1, F2
transaction GBT Restricted Stock Units Award $0 +42.4K $0.00 42.4K Sep 1, 2021 Common Stock 42.4K Direct F1, F3
transaction GBT Stock Option (Right to Buy) Award $0 +49.6K $0.00 49.6K Sep 1, 2021 Common Stock 49.6K $29.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F3 The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F4 The stock option vests with respect to 25% of the underlying shares on August 2, 2022 and in 12 equal quarterly installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.